MICROTECH MED-B (02235) announced its interim results for 2025, reporting revenue of approximately RMB 246 million, representing a year-on-year increase of 63.1%. Gross profit reached approximately RMB 127 million, up 57.7% compared to the same period last year. The net loss attributable to owners of the parent company was approximately RMB 2.29 million, narrowing by 93.9% year-on-year. Loss per share was RMB 0.005. According to the announcement, the significant growth in revenue and gross profit was primarily attributed to the rapid increase in domestic and international sales of continuous glucose monitoring systems. The reduction in net loss was mainly due to the company's expanded sales scale, enhanced comprehensive budget management and control, and improved operational efficiency through refined management practices.